Fidelity Management & Research Company

Activity in this selectionBiotech

By stage

Series C+5

Series B2

Biotech7

United States5

Australia1

United Kingdom1

7 in this selection

Aug 10

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Jul 8

Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies

$35MSeries C

Role not disclosed

Jun 8

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

$99.5MSeries B

Role not disclosed

May 6

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D

Role not disclosed

Jan 12

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B

Role not disclosed